RU2016131756A - Применение альфавируса в получении противоопухолевых лекарственных средств - Google Patents
Применение альфавируса в получении противоопухолевых лекарственных средств Download PDFInfo
- Publication number
- RU2016131756A RU2016131756A RU2016131756A RU2016131756A RU2016131756A RU 2016131756 A RU2016131756 A RU 2016131756A RU 2016131756 A RU2016131756 A RU 2016131756A RU 2016131756 A RU2016131756 A RU 2016131756A RU 2016131756 A RU2016131756 A RU 2016131756A
- Authority
- RU
- Russia
- Prior art keywords
- zap
- tumor
- cancer
- inhibitor
- alphavirus
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 2
- 102100023870 YLP motif-containing protein 1 Human genes 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 239000003112 inhibitor Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 241000710929 Alphavirus Species 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 7
- 238000002347 injection Methods 0.000 claims 4
- 239000007924 injection Substances 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002601 intratumoral effect Effects 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
Claims (19)
1. Способ лечения субъекта, предпочтительно субъекта-человека, имеющего опухоль, включающий введение субъекту одного или более альфавирусов, где указанный альфавирус выбран из вируса M1 и вируса Гета.
2. Способ по п. 1, где опухоль представляет собой опухоль с низкой экспрессией ZAP или ZAP-отрицательную опухоль.
3. Способ по п. 1, где опухоль представляет собой солидную опухоль с низкой экспрессией ZAP или ZAP-отрицательную солидную опухоль.
4. Способ по п. 1, где опухоль представляет собой рак печени, рак ободочной и прямой кишки, рак мочевого пузыря, рак молочной железы, рак шейки матки, рак предстательной железы, глиому, меланому, рак поджелудочной железы, назофарингеальную карциному, рак легкого или рак желудка.
5. Способ по п. 1, где опухоль представляет собой характеризующуюся низкой экспрессией ZAP или ZAP-отрицательную опухоль, выбранную из рака печени, рака ободочной и прямой кишки, рака мочевого пузыря, рака молочной железы, рака шейки матки, рака предстательной железы, глиомы, меланомы, рака поджелудочной железы, назофарингеальной карциномы, рака легкого и рака желудка.
6. Способ по п. 1, где альфавирус вводят посредством инъекции или перорально, предпочтительно посредством инъекции; предпочтительно альфавирус вводят посредством внутривенной инъекции или внутриопухолевой инъекции; более предпочтительно
a) вводят ежедневно в виде внутриопухолевой инъекции 2×105 БОЕ/кг – 2×109 БОЕ/кг; или
b) вводят ежедневно в виде внутривенной инъекции 2×106 БОЕ/кг – 2×1010 БОЕ/кг.
7. Способ по п. 1, где одновременно с введением указанного альфавируса или перед этим также вводят ингибитор ZAP.
8. Способ по п. 7, где ингибитор ZAP представляет собой нацеленный на опухоль ингибитор ZAP.
9. Способ по п. 7, где ингибитор ZAP выбран из ингибитора экспрессии и ингибитора функции ZAP.
10. Способ по п. 7, где ингибитор ZAP выбран из интерферирующего фрагмента для ZAP и антитела к ZAP.
11. Способ по п. 1, где субъекта до введения подвергают выявлению уровня экспрессии ZAP в опухоли, и
a) если опухоль характеризуется низкой экспрессией ZAP или отрицательной экспрессией ZAP, то указанный альфавирус вводят непосредственно;
b) если опухоль характеризуется нормальной экспрессией ZAP/высокой экспрессией ZAP, то до или во время введения вируса M1 обеспечивают ингибитор ZAP.
12. Способ по п. 11, где ингибитор ZAP представляет собой нацеленный на опухоль ингибитор ZAP.
13. Система введения противоопухолевых средств, содержащая реагент для выявления уровня экспрессии ZAP и альфавирус; где альфавирус представляет собой вирус M1 или вирус Гета.
14. Противоопухолевое лекарственное средство, содержащее альфавирус и ингибитор(ингибиторы) ZAP; где альфавирус представляет собой вирус M1 или вирус Гета.
15. Лекарственное средство по п. 14, где ингибитор ZAP представляет собой нацеленный на опухоль ингибитор ZAP.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410425510.3A CN104814984B (zh) | 2014-08-26 | 2014-08-26 | 甲病毒在制备抗肿瘤药物方面的应用 |
| CN201410425510.3 | 2014-08-26 | ||
| PCT/CN2015/087945 WO2016029833A1 (zh) | 2014-08-26 | 2015-08-24 | 甲病毒在制备抗肿瘤药物方面的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016131756A true RU2016131756A (ru) | 2018-02-07 |
| RU2693938C2 RU2693938C2 (ru) | 2019-07-08 |
Family
ID=53725628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016131756A RU2693938C2 (ru) | 2014-08-26 | 2015-08-24 | Применение альфавируса в получении противоопухолевых лекарственных средств |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10517909B2 (ru) |
| EP (1) | EP3187588B1 (ru) |
| JP (2) | JP6441372B2 (ru) |
| KR (2) | KR102125602B1 (ru) |
| CN (3) | CN107456463B (ru) |
| AU (1) | AU2015309403B2 (ru) |
| CA (1) | CA2939535C (ru) |
| HK (1) | HK1212925A1 (ru) |
| IL (1) | IL247082B2 (ru) |
| MX (1) | MX2016010058A (ru) |
| MY (1) | MY188734A (ru) |
| NZ (2) | NZ722768A (ru) |
| RU (1) | RU2693938C2 (ru) |
| SG (1) | SG11201606707RA (ru) |
| TW (1) | TWI609690B (ru) |
| WO (1) | WO2016029833A1 (ru) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107456463B (zh) | 2014-08-26 | 2022-10-14 | 广州威溶特医药科技有限公司 | 甲病毒在制备抗肿瘤药物方面的应用 |
| CN105233285B (zh) * | 2015-09-06 | 2018-10-12 | 广州威溶特医药科技有限公司 | Epac直接或间接激动剂与溶瘤病毒的联合应用 |
| CN105456302B (zh) * | 2015-12-23 | 2019-09-24 | 广州威溶特医药科技有限公司 | 大黄酚或其衍生物和溶瘤病毒在制备抗肿瘤药物的应用 |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN106265764B (zh) | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN108606982B (zh) * | 2016-08-18 | 2020-02-04 | 广州威溶特医药科技有限公司 | Vcp抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN109207491A (zh) * | 2017-07-05 | 2019-01-15 | 中国科学院武汉物理与数学研究所 | 一种m1病毒全长感染性克隆及制备方法及其在制备m1病毒中的应用 |
| CN109985242B (zh) * | 2017-12-29 | 2022-07-29 | 广州威溶特医药科技有限公司 | 甲羟戊酸代谢通路抑制剂和甲病毒在制备抗肿瘤药物的应用 |
| CN109985241A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| CN109985244A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| CN109985239A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | 极光激酶抑制剂和甲病毒在制备抗肿瘤药物的应用 |
| CN108635584B (zh) * | 2018-05-22 | 2021-12-21 | 广州威溶特医药科技有限公司 | 蛋白酶体抑制剂和甲病毒在制备抗肿瘤药物中的应用 |
| CN114668848A (zh) * | 2018-07-25 | 2022-06-28 | 广州威溶特医药科技有限公司 | 溶瘤病毒在制备抗肿瘤药物增效剂或耐药逆转剂方面的应用 |
| CN113939304B (zh) * | 2019-05-31 | 2024-02-23 | 广州威溶特医药科技有限公司 | M1病毒变异体及其应用 |
| CN111632146B (zh) * | 2020-05-29 | 2021-09-28 | 中山大学 | Oat抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| CN111544595B (zh) * | 2020-05-29 | 2021-10-26 | 中山大学 | 泛素结合酶e2抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| CN111603562A (zh) * | 2020-05-29 | 2020-09-01 | 中山大学 | 5-脂氧合酶抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| TWI778375B (zh) * | 2020-06-18 | 2022-09-21 | 大陸商廣州威溶特醫藥科技有限公司 | M1病毒變異體及其應用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141176A0 (en) * | 1998-07-30 | 2002-02-10 | Univ Johns Hopkins Med | Targeted alphavirus and alphaviral vectors |
| US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| AU2004252479A1 (en) * | 2003-06-06 | 2005-01-06 | Arborgen Llc. | Transcription factors |
| AU2005337612A1 (en) | 2005-10-28 | 2007-05-03 | David T. Curiel | Conditionally replicating viruses and methods for cancer virotherapy |
| US8481023B2 (en) * | 2006-09-15 | 2013-07-09 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| EE05462B1 (et) | 2007-08-31 | 2011-08-15 | Tartu �likool | Meetod viiruse genoomse raamatukogu moodustamiseks, viiruse genoomne raamatukogu ja komplekt selle moodustamiseks |
| US8435961B2 (en) | 2009-06-26 | 2013-05-07 | Massachusetts Institute Of Technology | Methods and compositions for increasing the activity of inhibitory RNA |
| BR112012013664B1 (pt) * | 2009-12-10 | 2020-11-10 | Turnstone Limited Partnership | rabdovírus oncolítico |
| CN104138375A (zh) | 2013-05-08 | 2014-11-12 | 南开大学 | 苯并吡啶类衍生物在制备抗hiv药物中的用途 |
| CN107456463B (zh) * | 2014-08-26 | 2022-10-14 | 广州威溶特医药科技有限公司 | 甲病毒在制备抗肿瘤药物方面的应用 |
-
2014
- 2014-08-26 CN CN201710666533.7A patent/CN107456463B/zh active Active
- 2014-08-26 CN CN201710516707.1A patent/CN107349226B/zh active Active
- 2014-08-26 CN CN201410425510.3A patent/CN104814984B/zh active Active
-
2015
- 2015-08-24 NZ NZ722768A patent/NZ722768A/en unknown
- 2015-08-24 TW TW104127467A patent/TWI609690B/zh active
- 2015-08-24 CA CA2939535A patent/CA2939535C/en active Active
- 2015-08-24 US US15/118,375 patent/US10517909B2/en active Active
- 2015-08-24 KR KR1020167021337A patent/KR102125602B1/ko active IP Right Grant
- 2015-08-24 NZ NZ74633815A patent/NZ746338A/en unknown
- 2015-08-24 WO PCT/CN2015/087945 patent/WO2016029833A1/zh active Application Filing
- 2015-08-24 RU RU2016131756A patent/RU2693938C2/ru active
- 2015-08-24 SG SG11201606707RA patent/SG11201606707RA/en unknown
- 2015-08-24 JP JP2016550515A patent/JP6441372B2/ja active Active
- 2015-08-24 MY MYPI2016702817A patent/MY188734A/en unknown
- 2015-08-24 KR KR1020187030942A patent/KR20180119706A/ko active Application Filing
- 2015-08-24 IL IL247082A patent/IL247082B2/en unknown
- 2015-08-24 MX MX2016010058A patent/MX2016010058A/es unknown
- 2015-08-24 EP EP15835808.5A patent/EP3187588B1/en active Active
- 2015-08-24 AU AU2015309403A patent/AU2015309403B2/en active Active
-
2016
- 2016-01-29 HK HK16101034.8A patent/HK1212925A1/zh unknown
-
2018
- 2018-11-21 JP JP2018218457A patent/JP2019048863A/ja active Pending
-
2019
- 2019-11-12 US US16/680,885 patent/US11235011B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016131756A (ru) | Применение альфавируса в получении противоопухолевых лекарственных средств | |
| PH12019501029A1 (en) | Fgfr4 inhibitor, preparation method therefor and pharmaceutical use therefor | |
| EA201890125A1 (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| WO2017176628A8 (en) | Methods for solid tumor treatment | |
| BR112018072872A2 (pt) | compostos de 1-tetra-hidropiranilcarbonil-2,3-di-hidro-1h-indol para tratar câncer | |
| RU2016148645A (ru) | Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого | |
| JP2017517506A5 (ru) | ||
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| EA201690905A1 (ru) | Специфические антитела против cd38 для лечения злокачественных новообразований у человека | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| MX2017015896A (es) | Agente anticancerigeno. | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| EA201590941A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| RU2018102963A (ru) | Производные анилинпиримидина и их применения | |
| JP2019510075A5 (ru) | ||
| RU2017104856A (ru) | Функционализированные и замещенные индолы в качестве противораковых средств | |
| RU2018127640A (ru) | Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников | |
| BR112018006157A2 (pt) | derivados de imidazo[4,5-b]piridina como inibidores duplos de dyrk1/clk1 | |
| EA201790788A1 (ru) | Жидкая фармацевтическая композиция, содержащая пеметрексед | |
| RU2017107681A (ru) | Производные хиназолина | |
| EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
| CY1124611T1 (el) | Θεραπειες μη-αλκοολικης στεατοηπατιτιδας (nash) | |
| MX2020001451A (es) | Tratamiento de cancer de mama triple negativo o cancer colorrectal con metastasis hepaticas con un anticuerpo anti-pd-l1 y un virus oncolitico. | |
| EA201992431A1 (ru) | Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса |